Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials
U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...
Pfizer
China’s CDE Announces “Care Plan” to Include Pfizer’s Marstaximab for Rare Disease Drug Development
The National Health Commission (NHC) of China, through its Center for Drug Evaluation (CDE), has...
Pfizer Partners with Shanghai Pharmaceutical for Long-Term Vaccine Collaboration in China
Pfizer Inc. (NSE: PFIZER, NYSE: PFE, ETR: PFE), a leading pharmaceutical company in the U.S.,...
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...
US FDA Approves Updated COVID-19 mRNA Vaccines from Pfizer/BioNTech and Moderna Ahead of Winter
The U.S. Food and Drug Administration (FDA) has granted approval to two updated mRNA COVID-19...
Pfizer’s Hemophilia Treatment Marstacimab Accepted for Review in China
The China Center for Drug Evaluation (CDE) has accepted for review a market approval filing...
Pfizer’s RSV Vaccine Abrysvo Shows Strong Protection in Immunocompromised Adults, Phase III Sub-Study Reveals
Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline...
Pfizer, Astellas, and University of California Sue Qilu Pharma Over Xtandi Patent Infringement
Pfizer Inc. (NYSE: PFE), through its subsidiary Medivation, and co-development partner Astellas Pharma Inc. (TYO:...
Pfizer Enters Multi-Year R&D Collaboration with Telescope Innovations to Leverage AI and Robotics
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has entered into a multi-year collaborative...
Pfizer Inc. Reports Q2 2024 Earnings with First Positive Growth Since Q4 2022 Peak
Pfizer Inc. (NYSE: PFE), a leading US pharmaceutical company, has announced its financial results for...
Pfizer’s Hemophilia A Gene Therapy Shows Promise in Phase III AFFINE Study
Pfizer Inc. (NYSE: PFE), a US pharmaceutical giant, has announced positive topline results from the...
Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs
Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...
Pfizer’s Once-Daily Danuglipron Selected for Full Clinical Development for Type 2 Diabetes and Obesity
Pfizer Inc. (NSE: PFIZER), a leading pharmaceutical company in the U.S., has announced that a...
Pfizer and AbbVie Announce Leadership Changes in Global R&D Divisions
In significant executive reshuffling, Pfizer Inc. (NYSE: PFE) and AbbVie (NYSE: ABBV) have both announced...
Pfizer Collaborates with Evotec for Drug Candidates in Metabolic and Infectious Diseases
Pfizer Inc. (NYSE: PFE) has entered into a multi-year collaboration with Germany-based biotechnology company Evotec...
Pharmaceutical Giants Face UK Industry Code Breach Allegations, Including Novartis and Pfizer
Several multinational pharmaceutical corporations have been reprimanded for violating the UK’s Prescription Medicines Code, a...
Qilu Pharmaceutical’s Generic Version of Vyndaqel Receives NMPA Marketing Approval
The National Medical Products Administration (NMPA) has granted marketing approval to Qilu Pharmaceutical’s generic version...
Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Misses Late-Stage Trial Endpoints
Pfizer Inc. (NYSE: PFE) has announced that a late-stage clinical trial for its investigational gene...
Pfizer Forges Partnership with Flagship Pioneering for Novel Obesity Treatments
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has initiated a strategic partnership with Flagship Pioneering, a...
Pfizer’s Lorbrena Outperforms Xalkori in 5-Year ALK-Positive NSCLC Follow-Up
Pfizer Inc. (NYSE: PFE) has announced the release of five-year follow-up data for its kinase...